Nuvation Bio (US:NUVB) Prnewswire·2026-02-17 21:05Core Viewpoint - Nuvation Bio Inc. will report its financial results for Q4 and the full year of 2025 on March 2, 2026, and will provide a business update during a conference call [1]. Company Overview - Nuvation Bio is a global oncology company focused on addressing significant challenges in cancer treatment, aiming to develop therapies that positively impact patients' lives [1]. - The company's diverse pipeline includes: - Taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor - Safusidenib, a brain-penetrant IDH1 inhibitor - NUV-868, a BD2-selective BET inhibitor - An innovative drug-drug conjugate (DDC) program [1]. Event Details - The conference call and webcast will take place on March 2, 2026, at 4:30 p.m. ET, and both investors and the public are invited to participate [1]. - Participants can access the live conference call by dialing +1 833-470-1428 (U.S. toll-free) and entering access code 833155 [1]. - An archived recording of the event will be available on Nuvation Bio's website for 90 days following the event [1].